Phase II evaluation of chlorozotocin in patients with renal cell carcinoma

A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.

Current oncology (Toronto, Ont.)·2020

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2014

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

Annals of oncology : official journal of the European Society for Medical Oncology·2014

Preclinical studies of gossypol in prostate carcinoma.

International journal of oncology·2011

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2006

Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.

Cancer treatment reports·1987

IV melphalan in children.

Cancer treatment reports·1987

Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.

Cancer treatment reports·1987

Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.

Cancer treatment reports·1987

Doxorubicin distribution in human breast cancer.

Cancer treatment reports·1987

Phase I study of echinomycin.

Cancer treatment reports·1987

Effects of Ciprofol- versus Remimazolam-Based Total Intravenous Anesthesia on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized Controlled Trial.

Drug design, development and therapy·2026

A berberine-functionalized green silver nanoplatform for combined chemo-photodynamic therapy against breast cancer cells.

Nanoscale advances·2026

Preclinical mechanistic study of rotundic acid against cyclophosphamide-induced nephrotoxicity in Swiss albino mice through modulation of oxidative stress, inflammation, apoptosis, and fibrosis via NF-κB/Caspase-3/TGF-β1 Pathways.

Biochemical and biophysical research communications·2026

Biological effects of N-acetylcysteine, calcium hydroxide, chlorhexidine and their combinations as intracanal medications: cytotoxicity, genotoxicity and cytokine modulation.

BDJ open·2026

Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan.

Anticancer research·2026

Comparing the real-world effectiveness of oral corticosteroids and antifungals for the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.

Chest·2026

Related Experiment Videos

Phase II evaluation of chlorozotocin in patients with renal cell carcinoma

Related Concept Videos

A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

Preclinical studies of gossypol in prostate carcinoma.

Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.

Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.

IV melphalan in children.

Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.

Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.

Doxorubicin distribution in human breast cancer.

Phase I study of echinomycin.

Effects of Ciprofol- versus Remimazolam-Based Total Intravenous Anesthesia on Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized Controlled Trial.

A berberine-functionalized green silver nanoplatform for combined chemo-photodynamic therapy against breast cancer cells.

Preclinical mechanistic study of rotundic acid against cyclophosphamide-induced nephrotoxicity in Swiss albino mice through modulation of oxidative stress, inflammation, apoptosis, and fibrosis via NF-κB/Caspase-3/TGF-β1 Pathways.

Biological effects of N-acetylcysteine, calcium hydroxide, chlorhexidine and their combinations as intracanal medications: cytotoxicity, genotoxicity and cytokine modulation.

Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan.

Comparing the real-world effectiveness of oral corticosteroids and antifungals for the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis.

Related Experiment Videos

Phase II evaluation of chlorozotocin in patients with renal cell carcinoma

Related Concept Videos

Related Articles